News and Trends 11 Dec 2014
After Merck’s Big Deal, Pfizer Collaborates with iTeos Therapeutics for Cancer Treatments
iTeos Therapeutics SA enters in a strategic collaboration with Pfizer Inc where iTeos will license to Pfizer rights to iTeos’ pre-clinical compounds targeting the enzymes expressed in many cancers. Pfizer will be responsible for the development and commercialization of IDO1 and TDO2 drug candidates. It completes a previous deal with Merck a few weeks ago. Additionally, […]
